Skip to content
NGL Fine Chem logo

NGL Fine Chem

NGLFINE NSE
₹2,653.20 +92.00 (+3.59%)
P/E
32.49
View as Markdown
MCP
Close 4 Nov 2026 ₹2,653.20 +1,184.00 +80.6% 1Y
Start ₹1,469.20

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Standalone · TTM

ROCE
16.70%
Debt to Equity
0.38
EPS (TTM)
₹81.65
Book Value
₹532.75
Market Cap
—
P/E (TTM)
32.49
P/B
4.98
ROE
15.60%
Dividend Yield
0.07%
EBITDA
₹87.40 Cr
52W High
₹3,602.00
52W Low
₹1,271.00
Day Range
₹2,531.80 – ₹2,683.90
Volume
2,001

Peer Comparison

Healthcare › Pharmaceuticals

NGL Fine Chem peer comparison
Sun Pharma
₹1,773.4038.81₹4,29,049 Cr4.770.90%16.00%20.50%₹61,631 Cr₹10,987 Cr
Divis Laboratories
₹10,037.5091.10₹2,65,269 Cr15.900.30%16.50%22.00%₹11,230 Cr₹2,925 Cr
Torrent Pharmaceuticals
₹4,738.5078.61₹1,77,061 Cr9.810.82%27.40%15.20%₹17,400 Cr₹2,099 Cr
Zydus Life Science
₹1,188.1026.44₹1,25,446 Cr4.370.08%21.20%21.10%₹28,592 Cr₹4,593 Cr
Laurus Labs
₹2,323.80114.81₹1,25,228 Cr20.720.04%18.30%17.80%₹7,270 Cr₹1,090 Cr
Dr Reddys Laboratories
₹1,374.0035.59₹1,14,543 Cr2.960.58%11.20%13.00%₹33,228 Cr₹3,184 Cr
Cipla
₹1,402.0033.59₹1,12,454 Cr3.200.93%11.60%15.50%₹28,324 Cr₹3,356 Cr
NGL Fine Chem (this company)
₹2,653.2032.49₹1,585 Cr4.980.07%15.60%16.70%₹525 Cr₹50 Cr
Median 8 companies₹2,048.6037.20₹1,25,337 Cr4.880.44%16.25%17.25%₹22,862 Cr₹3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

51 Average

Data confidence 100/100

insider_selling

Category scores

Quality
61
Good
Returns, margins, earnings quality 22% weight
Valuation
40
Weak
Cheap vs sector & own history 24% weight
Growth
98
Strong
Sales & profit trajectory 9% weight
Financial Health
61
Good
Solvency, leverage, coverage 9% weight
Momentum
43
Weak
Trend strength, vol-adjusted 12% weight
Ownership
47
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Company is expected to give good quarter

Weaknesses

2
  • Stock is trading at 5.77 times its book value
  • Company has a low return on equity of 12.7% over last 3 years.

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallBearish955
OscillatorsBearish351
Moving AveragesStrong Bearish604

Key readings

RSI (14)
44.11
Neutral
MACD (12,26,9)
−81.06
Bearish
SMA (50)
2,783.49
Bearish
SMA (200)
2,607.39
Bullish

As of

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10Y+17.68%
5Y+13.64%
3Y+21.15%
1Y+36.21%
TTM+41.13%

Net profit

Net profit growth by window
10Y+14.34%
5Y−5.25%
3Y+28.06%
1Y+133.33%
TTM+177.78%

Operating cash flow

Operating cash flow growth by window
10Y+15.90%
5Y+5.33%
3Y+3.03%
1Y+59.09%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y−9.01 pp
5Y−15.93 pp
3Y+3.36 pp
1Y+6.39 pp
TTM+6.45 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹100 Cr
Mar 2018₹114 Cr
Mar 2019₹153 Cr
Mar 2020₹152 Cr
Mar 2021₹258 Cr
Mar 2022₹319 Cr
Mar 2023₹275 Cr
Mar 2024₹329 Cr
Mar 2025₹359 Cr
Mar 2026₹489 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹15.00 Cr
Mar 2018₹13.00 Cr
Mar 2019₹20.00 Cr
Mar 2020₹11.00 Cr
Mar 2021₹55.00 Cr
Mar 2022₹52.00 Cr
Mar 2023₹20.00 Cr
Mar 2024₹39.00 Cr
Mar 2025₹18.00 Cr
Mar 2026₹42.00 Cr

Quarterly Results

₹ Cr
NGLFINE quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
69
79
85
96
88
91
87
93
101
117
126
145
137
Expenses
62
66
74
83
82
81
83
89
93
103
106
127
117
Operating Profit
8
13
11
13
6
11
4
4
8
14
20
18
20
OPM %
11%
17%
13%
13%
7%
12%
4.1%
4.2%
8%
12%
16%
12%
14%
Other Income
4
4
4
4
6
5
0
−1
7
2
5
3
7
Interest
0
0
0
0
0
0
1
1
1
1
1
1
1
Depreciation
2
2
2
2
2
2
2
3
3
4
4
4
4
PBT
9
15
13
14
10
13
1
0
10
11
19
15
22
Tax %
15%
24%
30%
24%
22%
25%
4%
44%
21%
26%
24%
24%
24%
Net Profit
8
11
9
11
8
10
1
−1
8
8
15
11
16
EPS (₹)
12.64
17.76
14.41
17.56
12.67
16.25
1.26
−0.84
12.37
12.79
23.86
18.37
26.63

Profit & Loss

₹ Cr
NGLFINE profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
88
96
100
114
153
152
258
319
275
329
359
489
525
Expenses
73
74
74
92
121
129
181
253
246
284
332
421
454
Operating Profit
15
22
25
22
32
23
77
66
29
45
27
68
71
OPM %
17%
23%
26%
19%
21%
15%
30%
21%
10%
14%
7%
14%
14%
Other Income
2
0
1
3
4
1
9
13
8
16
10
8
17
Interest
2
2
1
2
3
3
2
2
2
2
2.31
4.4
4
Depreciation
3
3
3
5
6
7
7
8
8
8
9
16
17
PBT
13
18
23
18
28
14
76
69
27
51
24
55
67
Tax %
35%
36%
35%
29%
27%
26%
27%
24%
24%
24%
24%
24%
—
Net Profit
8
11
15
13
20
11
55
52
20
39
18
42
50
EPS (₹)
13.48
18.45
24.1
20.38
32.58
17.16
89.79
84.57
32.57
62.35
29.35
67.38
81.65
Div. Payout %
0%
0%
0%
0%
5%
10%
2%
2%
5%
3%
6%
3%
—

Balance Sheet

₹ Cr
NGLFINE balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
3
3
3
3
3
3
3
3
3
3
3
3
Reserves
30
41
56
69
89
98
152
203
222
260
277
317
Borrowings
13
14
23
27
27
28
16
30
32
34
77
122
Other Liabilities
21
19
20
31
23
26
34
41
30
56
70
88
Total Liabilities
67
78
102
129
142
156
206
278
288
353
426
530
Fixed Assets
17
24
25
56
61
61
58
59
59
60
120
144
CWIP
1
2
16
3
0
0
1
6
26
46
50
95
Investments
2
3
6
6
9
14
33
32
43
57
63
43
Other Assets
46
49
55
63
73
80
115
180
159
190
193
248
Total Assets
67
78
102
129
142
156
206
278
288
353
426
530

Cash Flow

₹ Cr
NGLFINE cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
8
8
10
22
9
20
27
13
32
11
22
35
Investing
−3
−10
−10
−21
−10
−19
−24
−13
−24
−17
−58
−65
Financing
−4
2
0
0
0
−1
−1
−1
−1
−1
36
30
Net Cash Flow
1
0
0
1
−1
0
2
−1
7
−7
0
0
Free Cash Flow
5
−2
−8
−1
−6
12
22
−2
3
−17
−51
−51
CFO/OP
80
68
70
128
50
101
61
45
134
52
104
70

Ratios

NGLFINE financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
107
123
110
89
79
63
53
74
86
92
81
94
Inventory Days
106
90
114
134
106
154
132
133
69
99
95
101
Days Payable
150
122
139
187
92
114
94
84
59
110
94
89
Cash Conversion Cycle
63
91
85
35
93
103
91
124
97
82
83
106
Working Capital Days
38
49
45
18
70
63
71
89
67
71
51
59
ROCE %
29%
37%
34%
22%
28%
15%
52%
35%
12%
19%
8%
17%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view NGL Fine Chem insights

67 extracted metrics across FY11–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 72.49%
  • Public 22.59%
  • Others 4.87%
  • FIIs 0.04%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about NGL Fine Chem

What does NGL Fine Chem Ltd do?
Incorporated in 1981, NGL Fine-Chem Ltd is a manufacturer and exporter of pharmaceuticals and intermediates for usage in veterinary and human health.
Where is NGL Fine Chem Ltd (NGLFINE) listed?
NGL Fine Chem Ltd trades as NGLFINE on the NSE and under code 524774 on the BSE.
Which sector does NGL Fine Chem Ltd belong to?
NGL Fine Chem Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of NGL Fine Chem Ltd?
NGL Fine Chem Ltd trades at a PE ratio of 32.49 as of 4 Nov 2026, on earnings per share of ₹81.65, against a book value of ₹532.75 per share.
What is the 52-week high and low of NGL Fine Chem Ltd?
Over the last 52 weeks NGL Fine Chem Ltd has traded between ₹1,271 and ₹3,602 as of 4 Nov 2026.
Does NGL Fine Chem Ltd pay dividends?
NGL Fine Chem Ltd has a dividend yield of 0.07%.
What is the Return on Equity (ROE) of NGL Fine Chem Ltd?
NGL Fine Chem Ltd reported a return on equity of 15.60%. Its debt-to-equity ratio is 0.38.

Company Information

Incorporated in 1981, NGL Fine-Chem Ltd is a manufacturer and exporter of pharmaceuticals and intermediates for usage in veterinary and human health.

Website nglfinechem.com
CEO Mr. Rahul Jayant Nachane ACA, B. Com, DBF, MMS
Employees 520
Listed 8 Jul 2022
Face Value ₹5

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/NGLFINE.md for NGL Fine Chem Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month